Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline.
Journal of Clinical Oncology.
Times cited: 55
90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
European Journal of Cancer.
Times cited: 2